SCHEMBL142081

SCHEMBL142081

Cc1cccc(-c2nn(C(=S)Nc3ccccc3)cc2-c2ccnc3ccccc23)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 20/20 1.00
MAPK14 Q16539 5/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29350731 1.00 TGFBR1 (1.00) TGFBR1MAPK14
SCHEMBL21234477 0.89 TGFBR1 (0.80) TGFBR1MAPK14
SCHEMBL22477572 0.89 TGFBR1 (0.79) TGFBR1MAPK14
SCHEMBL29772701 0.87 TGFBR1 (0.77) TGFBR1MAPK14
SCHEMBL31256652 0.82 TGFBR1 (0.70) TGFBR1MAPK14
SCHEMBL30812495 0.81 TGFBR1 (0.68) TGFBR1MAPK14
SCHEMBL12096370 0.79 TGFBR1 (0.65) TGFBR1MAPK14
SCHEMBL23091679 0.78 TGFBR1 (0.64) TGFBR1MAPK14
SCHEMBL3244123 0.78 TGFBR1 (0.63) TGFBR1MAPK14
SCHEMBL18642502 0.77 GRM4 (0.65) TGFBR1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122038285-A Kit and method for constructing human bone organ by using pluripotent stem cells 广东医科大学附属医院 2026-05-15 CN claimed
US-20260049275-A1 INDUCED STEM CELLS UNIV MONASH (AU) 2026-02-19 US claimed
EP-3350313-B1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) 2025-11-26 EP claimed
EP-3047017-B1 METHODS OF MAMMALIAN RETINAL STEM CELL PRODUCTION AND APPLICATIONS UNIV CALIFORNIA (US) 2025-09-10 EP claimed
US-12371664-B2 Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby CHA BIOTECH CO., LTD. (KR) 2025-07-29 US claimed
WO-2025097221-A1 OPTIMIZED METHOD FOR GENERATING HUMAN SKIN ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS THE UNIVERSITY OF QUEENSLAND (AU) 2025-05-15 WO claimed
US-RE50313-E1 Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell CELLATOZ THERAPEUTICS, INC. (KR) 2025-02-25 US claimed
CN-118853572-A Culture medium for inducing amniotic epithelial cells to differentiate into neural stem cells and induction method 西安东澳生物科技有限公司 2024-10-29 CN claimed
US-12065671-B2 Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-08-20 US claimed
US-20240271089-A1 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-08-15 US claimed
US-8883502-B2 Expandable cell source of neuronal stem cell populations and methods for obtaining and using them THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-11 US claimed
EP-2799537-A1 NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS Kyoto Prefectural Public University Corporation (JP) 2014-11-05 EP claimed
US-20140120621-A1 TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING THE GENERAL HOSPITAL CORPORATION (US) 2014-05-01 US claimed
US-8603818-B1 TGF-beta receptor inhibitors to enhance direct reprogramming THE GENERAL HOSPITAL CORPORATION (US) 2013-12-10 US claimed
US-20130236436-A1 EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM ZHANG KANG (US) 2013-09-12 US claimed
US-20130071931-A1 PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY NATIONAL CANCER CENTER (JP) 2013-03-21 US claimed
US-8298825-B1 TGF-beta receptor inhibitors to enhance direct reprogramming THE GENERAL HOSPITAL CORPORATION (US) 2012-10-30 US claimed
EP-2497825-A1 Novel method for rapid and efficient generation of neuroectoderm cells and peripheral neurons from pluripotent stem cells Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-09-12 EP claimed
US-20120142093-A1 METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO NEURAL PRECURSOR CELLS KYOTO UNIVERSITY (JP) 2012-06-07 US claimed
US-20120058949-A1 Methods of Treating Neurological Disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049275-A1 INDUCED STEM CELLS SALL4, SOX18, LEF1 TGFBR1 110/4885MAPK14 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.